Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
A phase 2 trial evaluated resminostat as a maintenance treatment for patients with advanced-stage mycosis fungoides or Sézary syndrome. The study was multicenter, double-blind, and randomized, providing insights into the drug's efficacy in this rare skin lymphoma.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.